If you purchased Novo Nordisk securities during the Class Period you may be entitled to compensation without payment of any ...
We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Long-Term Pick. In this article, we will summarize ...
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
Wegovy maker Novo Nordisk is not immune to tariffs U.S. President Donald Trump is threatening to levy on the European Union, ...
Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...
Looking at options history for Novo Nordisk NVO we detected 8 trades. If we consider the specifics of each trade, it is ...
Novo Nordisk A/S failed to convince a federal judge that a pharmacy in Florida making compounded versions of its diabetes and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback